iShares Health Innovation Active ETF (BMED)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
iShares Health Innovation Active ETF (BMED) trades at $31.45 with AI Score 49/100 (Grade C). The iShares Health Innovation Active ETF aims to maximize total return by investing in innovative and emerging companies within the healthcare sector. Market cap: $4.77M, Sector: Financial services.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for BMED: BMED does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BMED against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BMED: the 1 perspectives are evenly split.
How is this calculated? →iShares Health Innovation Active ETF (BMED) Financial Services Profile
iShares Health Innovation Active ETF (BMED) focuses on maximizing total return through investments in innovative and emerging healthcare companies. As an actively managed ETF, BMED offers targeted exposure to the healthcare sector's dynamic landscape, providing investors with a specialized investment vehicle within the asset management industry.
What Is the Investment Thesis for BMED?
The iShares Health Innovation Active ETF (BMED) presents an investment opportunity centered on the growth potential of innovative healthcare companies. The fund's active management strategy allows for dynamic allocation to emerging trends and disruptive technologies within the healthcare sector. Key value drivers include the increasing demand for healthcare innovation, driven by an aging global population and advancements in medical technology. Catalysts include regulatory approvals for new therapies and devices, strategic partnerships, and successful product launches. Potential risks include regulatory hurdles, clinical trial failures, and competitive pressures within the healthcare industry. The fund's focus on innovation offers exposure to high-growth segments, but also introduces volatility associated with early-stage companies and evolving technologies.
Based on FMP financials and quantitative analysis
BMED Key Highlights
- BMED focuses on innovative and emerging companies in the healthcare sector, offering targeted exposure to high-growth segments.
- The fund is actively managed, allowing for flexibility in investment decisions and adaptation to changing market conditions.
- BMED's investment strategy aims to maximize total return by capitalizing on opportunities within the rapidly evolving healthcare landscape.
- The ETF provides a diversified portfolio of healthcare innovators, reducing risk compared to investing in individual companies.
- Managed by BlackRock, a leading global asset management firm, leveraging their expertise and resources in healthcare investing.
Who Are BMED's Competitors?
BMED is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NXDT NexPoint Diversified Real Estate Trust | $5.42 | +0.09% | $280.34M | 73 |
| GENB Generate Biomedicines, Inc. | $17.03 | -2.18% | $2.18B | 72 |
| SII Sprott Inc. | $118.11 | +2.72% | $3.05B | 71 |
| IDKFF ThreeD Capital Inc. | $0.08 | +5.49% | $5.70M | 70 |
| JHG Janus Henderson Group plc | $51.95 | -0.04% | $8.00B | 62 |
| TRNGF The Trendlines Group Ltd. | $0.03 | +2.95% | $28.87M | 62 |
| ARES Ares Management Corporation | $121.81 | +4.20% | $40.01B | 62 |
| JBARF Julius Bär Gruppe AG | $93.79 | +3.66% | $19.23B | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BMED's Key Strengths?
- Focus on innovative and emerging healthcare companies.
- Active management strategy.
- Diversified portfolio.
- Expertise of BlackRock.
What Are BMED's Weaknesses?
- Higher expense ratio compared to passive ETFs.
- Potential for underperformance compared to benchmark indices.
- Reliance on the expertise of the portfolio managers.
- Vulnerability to market volatility in the healthcare sector.
What Could Drive BMED Stock Higher?
- Regulatory approvals for new therapies and medical devices.
- Technological advancements in healthcare, such as AI and gene editing.
- Increasing healthcare spending and demand for innovative solutions.
- Strategic partnerships and collaborations between healthcare companies.
What Are the Key Risks for BMED?
- Regulatory hurdles and delays in drug approvals.
- Clinical trial failures and product recalls.
- Competitive pressures from other healthcare companies.
- Market volatility and economic uncertainty.
- Changes in healthcare policy and reimbursement rates.
What Are the Growth Opportunities for BMED?
- Increased Healthcare Spending: The global healthcare expenditure is projected to reach $10 trillion by 2028, driven by an aging population and rising chronic diseases. BMED can capitalize on this trend by investing in companies developing innovative solutions to address these healthcare challenges. This includes companies focused on telemedicine, remote patient monitoring, and personalized medicine, which are expected to experience significant growth in the coming years. The timeline for realizing this growth is ongoing, as healthcare spending continues to increase year over year.
- Technological Advancements: Rapid advancements in healthcare technology, such as artificial intelligence, gene editing, and robotics, are creating new opportunities for innovation. BMED can invest in companies at the forefront of these technological breakthroughs, potentially generating high returns. The market for AI in healthcare, for example, is projected to reach $34 billion by 2027. The timeline for this growth is near-term, as these technologies are already being implemented in various healthcare settings.
- Emerging Markets Growth: Healthcare spending in emerging markets is growing at a faster rate than in developed countries, driven by increasing incomes and access to healthcare services. BMED can invest in companies that are expanding their presence in these markets, tapping into a new source of growth. The emerging markets healthcare sector is expected to grow at a CAGR of 8-10% over the next five years. The timeline for this growth is medium-term, as these markets continue to develop and expand their healthcare infrastructure.
- Personalized Medicine: The shift towards personalized medicine, which tailors treatments to individual patients based on their genetic makeup and other factors, is creating new opportunities for targeted therapies and diagnostics. BMED can invest in companies developing personalized medicine solutions, which are expected to revolutionize healthcare. The personalized medicine market is projected to reach $2.4 trillion by 2028. The timeline for this growth is medium to long-term, as personalized medicine becomes more widely adopted and integrated into healthcare systems.
- Aging Population: The global population is aging, with the number of people aged 65 and older projected to double by 2050. This demographic shift is driving increased demand for healthcare services and products, particularly those focused on age-related diseases and conditions. BMED can invest in companies developing innovative solutions to address the needs of the aging population, such as geriatric care, assisted living technologies, and treatments for age-related diseases. The timeline for this growth is ongoing, as the aging population continues to increase.
What Opportunities Does BMED Have?
- Growth in healthcare spending and technological advancements.
- Expansion into new markets and investment strategies.
- Increasing demand for healthcare-focused investment products.
- Potential for outperformance through active management.
What Threats Does BMED Face?
- Regulatory changes in the healthcare industry.
- Competition from other healthcare ETFs and investment products.
- Market downturns and economic uncertainty.
- Clinical trial failures and product recalls.
What Are BMED's Competitive Advantages?
- Expertise of BlackRock in healthcare investing.
- Active management strategy allows for flexibility and adaptation to market changes.
- Diversified portfolio reduces risk compared to investing in individual companies.
- Targeted exposure to innovative and emerging healthcare companies.
What Does BMED Do?
The iShares Health Innovation Active ETF (BMED) is designed to provide investors with exposure to the innovative and emerging segments of the healthcare industry. As an actively managed exchange-traded fund, BMED seeks to achieve maximum total return by strategically investing in companies that are at the forefront of healthcare advancements. The fund's investment strategy focuses on identifying and capitalizing on opportunities within the rapidly evolving healthcare sector, which includes biotechnology, pharmaceuticals, medical devices, healthcare technology, and related fields. BMED aims to provide a diversified portfolio of healthcare innovators, allowing investors to participate in the potential growth and advancements within this critical sector. The fund's active management approach allows for flexibility in investment decisions, enabling the portfolio managers to adapt to changing market conditions and identify emerging trends within the healthcare industry. By focusing on innovation, BMED seeks to capture the long-term growth potential of companies that are driving advancements in healthcare technology, treatments, and services. The ETF is managed by BlackRock, a leading global asset management firm, leveraging their expertise and resources in healthcare investing.
What Products and Services Does BMED Offer?
- Invests in innovative and emerging companies in the healthcare sector.
- Seeks to maximize total return through strategic asset allocation.
- Provides investors with targeted exposure to the healthcare industry.
- Actively manages a portfolio of healthcare stocks.
- Focuses on companies driving advancements in healthcare technology and services.
- Offers a diversified investment vehicle for participating in the growth of the healthcare sector.
How Does BMED Make Money?
- Generates revenue through management fees charged to investors.
- Invests in a portfolio of healthcare companies to generate capital appreciation.
- Utilizes an active management strategy to identify and capitalize on investment opportunities.
- Distributes capital gains to investors.
What Industry Does BMED Operate In?
The asset management industry is characterized by a diverse range of investment vehicles, including ETFs, mutual funds, and hedge funds. The iShares Health Innovation Active ETF (BMED) operates within this landscape, focusing specifically on the healthcare sector. The healthcare industry is experiencing significant growth, driven by factors such as an aging population, technological advancements, and increasing healthcare spending. BMED's focus on innovation positions it to capitalize on these trends, while also navigating the competitive landscape of other healthcare-focused investment products.
Who Are BMED's Key Customers?
- Individual investors seeking exposure to the healthcare sector.
- Institutional investors looking for diversified healthcare investments.
- Financial advisors seeking to provide clients with healthcare-focused investment options.
- Retirement funds and pension plans.
iShares Health Innovation Active ETF (BMED) Valuation Context
Valued at $4.77M, BMED is classified as a micro-cap stock. Relative to its peer group, BMED's quantitative score of 49/100 is below the peer average of 70/100.
ROE 0%Key Financial Metrics
Return on equity for iShares Health Innovation Active ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. BMED trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
BMED Financials
Bull Case vs Bear Case
Bull Case
- BMED's focus on innovative healthcare companies positions it well for long-term growth, especially with aging populations globally.
- Recent insider buying activity suggests confidence in the fund's future performance and underlying holdings.
- Community sentiment indicates growing interest in healthcare innovation as a key investment area, potentially driving demand for BMED.
- The market is increasingly recognizing the potential of disruptive technologies in healthcare, which could benefit BMED's portfolio companies.
Bear Case
- Healthcare innovation is inherently risky, with many companies facing regulatory hurdles and clinical trial failures.
- Community discussions reveal concerns about the high valuations of some healthcare technology companies within BMED's portfolio.
- Market perception of the healthcare sector can be volatile, influenced by political factors and policy changes.
- Recent market developments suggest increased competition among healthcare innovation ETFs, potentially diluting BMED's appeal.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BMED Latest News
No recent news available for BMED.
BMED Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BMED.
Price Targets
Wall Street price target analysis for BMED.
BMED MoonshotScore
What does this score mean?
The MoonshotScore rates BMED's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Common Questions About BMED (Financial Services)
What does iShares Health Innovation Active ETF do?
The iShares Health Innovation Active ETF (BMED) is an actively managed fund that invests in companies at the forefront of healthcare innovation. Its primary goal is to maximize total return by strategically allocating capital to emerging and disruptive companies within the healthcare sector. The fund focuses on areas such as biotechnology, medical devices, healthcare technology, and pharmaceuticals. By actively managing its portfolio, BMED aims to capitalize on the growth potential of innovative healthcare companies, while also mitigating risk through diversification and strategic asset allocation within the financial services sector.
What are the main risks for BMED?
The iShares Health Innovation Active ETF (BMED) faces several risks inherent to its focus on innovative healthcare companies. These include regulatory risks associated with drug approvals and healthcare policies, clinical trial risks related to the development of new therapies, and competitive risks from other companies in the healthcare sector. Market volatility and economic uncertainty can also impact the fund's performance. Additionally, the active management strategy introduces the risk of underperformance compared to benchmark indices if the portfolio managers' investment decisions are not successful. These risks should be carefully considered by investors before investing in BMED.
What are the key factors to evaluate for BMED?
iShares Health Innovation Active ETF (BMED) holds an AI score of 49/100 (low). Not financial advice.
How frequently does BMED data refresh on this page?
BMED prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BMED's recent stock price performance?
iShares Health Innovation Active ETF (BMED) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on innovative and emerging healthcare companies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BMED overvalued or undervalued right now?
Valuing iShares Health Innovation Active ETF (BMED) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BMED?
Before investing in iShares Health Innovation Active ETF (BMED), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BMED to a portfolio?
Key strength of iShares Health Innovation Active ETF (BMED): Focus on innovative and emerging healthcare companies. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending for BMED, which may provide additional insights into the company's performance and prospects.
- The information provided is based on available data and may be subject to change.
- Investment decisions should be made based on individual risk tolerance and financial circumstances.